{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:36:15Z","timestamp":1793136975887,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["LD202031"],"award-info":[{"award-number":["LD202031"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32471456"],"award-info":[{"award-number":["32471456"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302622"],"award-info":[{"award-number":["82302622"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L2606003"],"award-info":[{"award-number":["L2606003"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-2019AZMS-0055"],"award-info":[{"award-number":["Y-2019AZMS-0055"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["Q21H160017"],"award-info":[{"award-number":["Q21H160017"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2507000"],"award-info":[{"award-number":["2023YFC2507000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Talanta"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.talanta.2026.130466","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:22:46Z","timestamp":1787034166000},"page":"130466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PB","title":["Peptide-functionalized magnetic nanobeads for EpCAM-targeted CTC isolation and immunotherapy efficacy evaluation in liver cancer"],"prefix":"10.1016","volume":"312","author":[{"given":"Xuejie","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangpeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6004-1865","authenticated-orcid":false,"given":"Yongyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.talanta.2026.130466_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.talanta.2026.130466_bib2","first-page":"7","article-title":"Cancer statistics","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.talanta.2026.130466_bib3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jhep.2024.10.031","article-title":"Liver cancer in 2021: Global burden of disease study","volume":"82","author":"Tan","year":"2025","journal-title":"J. Hepatol."},{"issue":"7725","key":"10.1016\/j.talanta.2026.130466_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41586-018-0519-y","article-title":"Necroptosis microenvironment directs lineage commitment in liver cancer","volume":"562","author":"Seehawer","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.talanta.2026.130466_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216799","article-title":"Characterization of the distinct immune microenvironments between hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"588","author":"Jiang","year":"2024","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.talanta.2026.130466_bib6","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41416-018-0007-z","article-title":"Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the liver cancer pooling project","volume":"118","author":"Petrick","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.talanta.2026.130466_bib7","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nrclinonc.2015.121","article-title":"Advances in targeted therapies for hepatocellular carcinoma in the genomic era","volume":"12","author":"Llovet","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.talanta.2026.130466_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/jamaoncol.2020.3381","article-title":"The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review","volume":"7","author":"Pinter","year":"2021","journal-title":"JAMA Oncol."},{"issue":"10064","key":"10.1016\/j.talanta.2026.130466_bib9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.talanta.2026.130466_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, Double-Blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.talanta.2026.130466_bib11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.talanta.2026.130466_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41575-019-0229-4","article-title":"Tumour evolution in hepatocellular carcinoma","volume":"17","author":"Craig","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.talanta.2026.130466_bib13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ccell.2024.03.004","article-title":"Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer","volume":"42","author":"Yang","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.talanta.2026.130466_bib14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.29486","article-title":"Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: a systematic review and meta-analysis","volume":"67","author":"Finn","year":"2018","journal-title":"Hepatology"},{"issue":"Pt 1","key":"10.1016\/j.talanta.2026.130466_bib15","article-title":"Site-specific N-glycan alterations on haptoglobin as potential biomarkers for distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma","volume":"280","author":"Liu","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"2","key":"10.1016\/j.talanta.2026.130466_bib16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","article-title":"Precision treatment in advanced hepatocellular carcinoma","volume":"42","author":"Yang","year":"2024","journal-title":"Cancer Cell"},{"issue":"10088","key":"10.1016\/j.talanta.2026.130466_bib17","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.talanta.2026.130466_bib18","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.talanta.2026.130466_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071760","article-title":"Utilization of immunotherapy for the treatment of hepatocellular carcinoma in the peri-transplant setting: transplant oncology view","volume":"14","author":"Abdelrahim","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.talanta.2026.130466_bib20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.talanta.2026.130466_bib21","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.talanta.2026.130466_bib22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.talanta.2026.130466_bib23","unstructured":"W. Le, S. Hu, P. Zhang, Y. Wang, Y. Hu, Z. Cui, B. Chen, Capture of live circulating tumor cells via unique surface charges from cancer patients by a novel nanotechnology, Interdisciplinary Medicine n\/a(n\/a) e20240045."},{"issue":"4","key":"10.1016\/j.talanta.2026.130466_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/INMD.20230021","article-title":"Recent advances of liquid biopsy: interdisciplinary strategies toward clinical decision-making","volume":"1","author":"Bao","year":"2023","journal-title":"Interdisciplinary Medicine"},{"issue":"1","key":"10.1016\/j.talanta.2026.130466_bib25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41392-021-00817-8","article-title":"Circulating tumor cells: biology and clinical significance","volume":"6","author":"Lin","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.talanta.2026.130466_bib26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12943-023-01870-3","article-title":"Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation","volume":"22","author":"Wang","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.talanta.2026.130466_bib27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.31165","article-title":"Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma","volume":"73","author":"Ahn","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.talanta.2026.130466_bib28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","article-title":"Molecular principles of metastasis: a hallmark of cancer revisited","volume":"5","author":"Fares","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"7586","key":"10.1016\/j.talanta.2026.130466_bib29","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature17038","article-title":"Metastatic colonization by circulating tumour cells","volume":"529","author":"Massague","year":"2016","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.talanta.2026.130466_bib30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","article-title":"Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells","volume":"19","author":"Keller","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.talanta.2026.130466_bib31","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrc3820","article-title":"Challenges in circulating tumour cell research","volume":"14","author":"Alix-Panabieres","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.talanta.2026.130466_bib32","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1438111","article-title":"Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy","volume":"7","author":"Yue","year":"2018","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.talanta.2026.130466_bib33","doi-asserted-by":"crossref","first-page":"e2227","DOI":"10.1002\/onco.13981","article-title":"Assessment of PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with cancer receiving PD-1\/PD-L1 blockade therapies","volume":"26","author":"Tan","year":"2021","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.talanta.2026.130466_bib34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.talanta.2026.130466_bib35","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.21037\/jtd-20-1026A","article-title":"Efficient isolation and quantification of circulating tumor cells in non-small cell lung cancer patients using peptide-functionalized magnetic nanoparticles","volume":"12","author":"Liang","year":"2020","journal-title":"J. Thorac. Dis."},{"issue":"26","key":"10.1016\/j.talanta.2026.130466_bib36","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1039\/C4TB00456F","article-title":"Peptide-based isolation of circulating tumor cells by magnetic nanoparticles","volume":"2","author":"Bai","year":"2014","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.talanta.2026.130466_bib37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12935-019-0738-9","article-title":"Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis","volume":"19","author":"Liu","year":"2019","journal-title":"Cancer Cell Int."}],"container-title":["Talanta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914026011227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914026011227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:30:48Z","timestamp":1793136648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039914026011227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":37,"alternative-id":["S0039914026011227"],"URL":"https:\/\/doi.org\/10.1016\/j.talanta.2026.130466","relation":{},"ISSN":["0039-9140"],"issn-type":[{"value":"0039-9140","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptide-functionalized magnetic nanobeads for EpCAM-targeted CTC isolation and immunotherapy efficacy evaluation in liver cancer","name":"articletitle","label":"Article Title"},{"value":"Talanta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.talanta.2026.130466","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"130466"}}